Bruton’s tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence

Tomás José González-López, Rick Kapur

Open source

DOI
10.1016/j.bvth.2026.100223
Published
2026-11
Container
Blood Vessels, Thrombosis & Hemostasis
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.bvth.2026.100223,
  title = {Bruton’s tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence},
  author = {Tomás José González-López and Rick Kapur},
  year = {2026},
  journal = {Blood Vessels, Thrombosis \& Hemostasis},
  doi = {10.1016/j.bvth.2026.100223},
  url = {https://doi.org/10.1016/j.bvth.2026.100223}
}

RIS

TY  - JOUR
TI  - Bruton’s tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence
AU  - Tomás José González-López
AU  - Rick Kapur
PY  - 2026
JO  - Blood Vessels, Thrombosis & Hemostasis
DO  - 10.1016/j.bvth.2026.100223
UR  - https://doi.org/10.1016/j.bvth.2026.100223
ER  - 

APA

González-López, T. J., & Kapur, R. (2026). Bruton’s tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence. Blood Vessels, Thrombosis & Hemostasis. https://doi.org/10.1016/j.bvth.2026.100223

Source records